What is the recommended treatment for polymyalgia rheumatica?

Polymyalgia Rheumatica Treatment

Start oral prednisone 12.5-25 mg daily immediately upon diagnosis, then taper gradually to 10 mg/day within 4-8 weeks, followed by 1 mg reductions every 4 weeks until discontinuation while monitoring for relapse. 1

Initial Treatment Strategy

The cornerstone of PMR treatment is glucocorticoids, specifically oral prednisone or equivalent. The 2015 EULAR/ACR guidelines provide clear dosing parameters:

• Starting dose: 12.5-25 mg prednisone equivalent daily 1
• Use the higher end (20-25 mg) for patients at high risk of relapse with low risk of adverse events
• Use the lower end (12.5-15 mg) for patients with comorbidities like diabetes, osteoporosis, glaucoma, hypertension, or cardiovascular disease 1
• Strongly avoid doses >30 mg/day - patients requiring this should be evaluated for alternative diagnoses 1
• Avoid doses ≤7.5 mg/day as initial therapy - insufficient for disease control 1

Clinical improvement should occur within 2 weeks, with near-complete response by 4 weeks. If no improvement occurs, reconsider the diagnosis. 1

Glucocorticoid Tapering Protocol

The tapering schedule is critical to minimize both relapse and cumulative steroid exposure:

Phase 1: Initial Tapering (Weeks 0-8)

• Reduce from starting dose to 10 mg/day within 4-8 weeks 1
• Monitor disease activity and inflammatory markers closely

Phase 2: Slow Tapering (After achieving remission)

• Reduce by 1 mg every 4 weeks (or 1.25 mg using alternate-day schedules like 10/7.5 mg) 1
• Continue until complete discontinuation if remission maintained
• This slow taper is essential - faster tapering does not appear to improve outcomes and may increase relapse risk 2

Relapse Management

• Increase prednisone back to pre-relapse dose 1
• Taper gradually over 4-8 weeks back to the dose where relapse occurred
• Consider adding steroid-sparing agents at this point

Pre-Treatment Assessment (Critical)

Before initiating glucocorticoids, document:

• Comorbidities increasing steroid risk: hypertension, diabetes, glucose intolerance, cardiovascular disease, dyslipidemia, peptic ulcer, osteoporosis (especially recent fractures), cataracts, glaucoma risk, chronic infections, NSAID use 1
• Risk factors for relapse: female sex, high ESR (>40 mm/hr), peripheral inflammatory arthritis 1
• Baseline inflammatory markers (ESR, CRP)
• Minimal clinical dataset for monitoring

Steroid-Sparing Agents

Methotrexate

Consider adding methotrexate 7.5-10 mg/week orally in patients with:

• High risk for glucocorticoid-related adverse events
• High risk for relapse or prolonged therapy
• Relapsing disease despite appropriate glucocorticoid management 1

The evidence for methotrexate shows moderate benefit in reducing cumulative glucocorticoid doses and improving remission rates, though the effect is modest 3. It remains the traditional first-line steroid-sparing agent despite limited efficacy 4, 5.

IL-6 Receptor Inhibitors (Emerging Standard)

Tocilizumab and sarilumab demonstrate superior efficacy as steroid-sparing agents with consistent evidence from multiple high-quality trials 6, 7:

• Higher remission rates compared to glucocorticoids alone
• Significant reduction in cumulative glucocorticoid exposure
• Particularly valuable in relapsing disease
• Consider in new-onset PMR with high risk for glucocorticoid adverse events 7

These biologics represent a significant advancement over traditional approaches, though cost and availability may limit use 8, 4.

Alternative Options

• Rituximab: Shows promise but requires further validation 6, 7
• Tofacitinib (JAK inhibitor): Preliminary evidence suggests benefit but needs more study 6
• TNF-α blockers: Strongly avoid - proven ineffective in PMR 1, 3

Alternative Glucocorticoid Formulation

Intramuscular methylprednisolone (120 mg every 3 weeks initially) may be considered as an alternative to oral prednisone, particularly in:

• Female patients with difficult-to-control hypertension, diabetes, osteoporosis, or glaucoma
• Situations where lower cumulative glucocorticoid dose is desirable 1

Important caveats: Evidence is limited to a single RCT, showed reduced weight gain but no other significant reduction in adverse events, and is not available in all countries 1. This remains a conditional recommendation only.

Monitoring and Follow-Up

Structured follow-up schedule:

• First year: Every 4-8 weeks 1
• Second year: Every 8-12 weeks 1
• During tapering or relapse: As clinically indicated

At each visit assess:

• Disease activity and symptoms
• Inflammatory markers (ESR, CRP)
• Glucocorticoid-related adverse events
• Adherence to tapering schedule

Specialist Referral Indications

Refer to rheumatology for:

• Atypical presentation: peripheral inflammatory arthritis, systemic symptoms, low inflammatory markers, age <60 years 1
• High risk or evidence of steroid-related side effects
• Refractory disease or frequent relapses
• Need for prolonged therapy
• Consideration of biologic agents 1

Common Pitfalls to Avoid

1. Starting doses too high (>30 mg) or too low (≤7.5 mg) - both associated with worse outcomes 1
2. Tapering too quickly - increases relapse risk without clear benefit 2
3. Using NSAIDs as primary therapy - strongly discouraged; glucocorticoids are superior 1
4. Failing to assess comorbidities before starting steroids - missed opportunity to prevent complications 1
5. Not considering steroid-sparing agents early in high-risk patients - leads to excessive cumulative steroid exposure 1
6. Attempting TNF-α blockers - proven ineffective, waste of resources 1, 3

Additional Supportive Measures

• Individualized exercise program: Recommended for maintaining muscle mass, function, and reducing fall risk, especially in older/frail patients on long-term glucocorticoids 1, 7
• Patient education: Focus on disease impact, treatment expectations, and self-monitoring for flares 1
• Ensure rapid access to medical advice for reporting flares or adverse events 1